Global Partners LP
GLP · NYSE48.63
48.63
USD0.410.85%วันที่
สัญลักษณ์
พาดหัว
แหล่งที่มา
Logistics giants are racing to keep up with healthcare boom as GLP-1s highlight need for cold storage
CNBC
Jim Cramer says he's standing by Eli Lilly after rival's GLP-1 lawsuit. Here's why
CNBC
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising - CNBC
CNBC
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss - CNBC
CNBC
Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage
CNBC
As the GLP-1 race heats up, how can investors position themselves for the next wave of innovation? (LLY:NYSE) - Seeking Alpha
Seeking Alpha
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage - CNBC
CNBC
Amazon launches GLP-1 weight loss program, promising'fast, convenient' access
CNBC
Eli Lilly taps into its GLP-1 windfall, while Honeywell sheds a lower-margin unit
CNBC
RFK Jr.'s peptide policy could boost Hims & Hers as its GLP-1 business evolves - CNBC
CNBC
As millions lose weight on GLP-1s, they're starting to turn to retailers to refresh their wardrobes
CNBC
Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
CNBC
GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up
CNBC
Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says - CNBC
CNBC
Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients
CNBC
Fancy clothes, mealtime alarms and Disney princess gigs: How GLP-1s are changing people's lives in unexpected ways
CNBC
Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China
CNBC
What the initial frenzy over GLP-1 drugs can teach us about the current market
CNBC
What signal Lilly sends by stockpiling its GLP-1 weight loss pills ahead of FDA approval
CNBC
Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
CNBC
This top stock-picker spotted Nvidia and GLP-1s early — and made over 200%. Here’s what he’s buying now.
MarketWatch
Half of GLP-1 users ditch their injections — and some are turning to other weight-loss methods instead
MarketWatch
Novo Nordisk CEO explains why new GLP-1 pill expands access to the weight loss drugs
CNBC
Novo Nordisk Launches $149 Wegovy Pill, Expanding Access to GLP-1 Weight-Loss Drugs
Decrypt
FDA approves first GLP-1 pill for weight loss - Axios
Axios
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk - CNBC
CNBC
GRVT GLP Strategy Reopened, Funding Cap Raised to $7.5M on Grvt’s Decentralized Perpetual Platform
CoinOtag
There’s still hope GLP-1 drugs could slow the second-biggest type of dementia
MarketWatch
Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s as hoped, and the stock tumbles
MarketWatch
Is GLP-1 the new AI? Drugmaker Eli Lilly briefly joined the $1 trillion market cap club.
MarketWatch
Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
CNBC
Tariffs and GLP-1s are keeping people from dining out. An analyst tries to find the positives.
MarketWatch
GLP-1 drugs could save millions of lives — and spark a pension crisis
MarketWatch
Hacked Perp DEX GMX to Repay $44M to Arbitrum GLP Holders After Exploit
cryptonews
Why GLP-1s could become the "everything drug" - Axios
Axios
GMX Recovers $42 Million GLP Funds on Arbitrum After V1 Vulnerability Attack
CoinOtag
GMX Hack Exploits GLP Token Vulnerability, Potential Partial Recovery of Stolen Ethereum
CoinOtag
GMX Faces $40 Million V1 GLP Pool Exploit, Raising Questions on DeFi Leverage Security
CoinOtag
GMX V1 Faces Possible Exploit Impacting GLP Pool Amid Ongoing Crypto Security Concerns in 2025
CoinOtag
GMX V1 GLP Pool on Arbitrum Hit by $40M Attack; Trading Suspended to Protect Users
CoinOtag
Market Voices: July Fed rate cut eyed, GLP-1s, Darden, Aflac, JPMorgan
SeekingAlpha
Just how many Americans are taking GLP-1s now - Axios
Axios
Hims & Hers shares tumble 18% as margin miss adds to concerns about GLP-1 business
CNBC
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease - Fortune
Fortune
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’
MarketWatch
WeightWatchers’ stock soars after adding compounded GLP-1 treatment to its offering
MarketWatch
Obesity drugs in kindergarten? Novo Nordisk GLP-1 drug works for kids as young as 6, study finds.
MarketWatch
Obesity drugs’ next wave: These companies could snag 20% of GLP-1 market, analysts say
MarketWatch
For Alzheimer’s patients, this Novo Nordisk GLP-1 drug slows cognitive decline, study finds
MarketWatch
คำถามที่พบบ่อย
คุณกำลังรออะไร?เริ่มทำกำไรวันนี้
©
2026
สงวนลิขสิทธิ์ทุกประการ